American College of Rheumatology

A UK team reporting at the American College of Rheumatology Annual Meeting in San Francisco, CA said it found that adalimumab (Humira/AbbVie) helped patients who had active JIA-associated uveitis

Study results show treatment with tofacitinib imrpveos symptoms in patients with ankylosing spondylitis.

A multinational group known as GRAPPA has compiled a new set of treatment recommendations for psoriasis and psoriatic arthritis.

Giant cell arteritis is effectively treated with glucocorticoids, but they have side effects and patients tend to relapse. Researchers evaluated abatacept combined with prednisone and saw fewer relapses.

A research team in the UK looked at how well rituximab (Rituxan/Genentech) improved the Sjogren's Syndrome symptoms of fatigue and dry mouth.

Although gout has historically been thought to be a rare in patients with SLE, a recent case series suggests that the incidence of gout in SLE may be greater than previously thought, University of Michigan researchers report.

Reporting at the American College of Rheumatology Annual Meeting in San Francisco, a team from Japan reported on a novel humanized monoclonal antibody called E6011, one that targets fractalkine-CX3CR1, with a research goal of stopping the chemokine's accumulation in inflamed tissues in rheumatoid arthritis.

Researchers have found several urinary biomarkers that may be used to predict rheumatoid arthritis activity and prognosis.

Compared to placebo and treatment with adalimumab, treatment with once-daily oral baricitinib was associated with significant clinical improvements in patients with rheumatoid arthritis.

Intra-articular injection of two widely used plant and mineral extract-based formulations provide long-lasting pain relief in patients with moderate to severe pain from knee osteoarthritis, according to the first-ever double-blind trial of the treatments.

A "biosimilar" form of etanercept is clinically equivalent to the branded form for rheumatoid arthritis, according to data presented at the 2014 annual meeting of the American College of Rheumatology.

A blood test may offer a reliable way to identify rheumatoid arthritis patients who are unlikely to respond to anti-tumor necrosis factor-alpha inhibitors, speeding treatment with other drugs and lowering costs.

Women using intrauterine devices with a family history of rheumatoid arthritis are at greater risk for the condition.

Running does not increase the risk for knee osteoarthritis (OA), according to study results presented at the 2014 annual meeting of the American College of Rheumatology. No increase in knee OA or knee pain was associated with habitual running in any age group in a study of over 600 individuals who reported running as a regular activity at some point in their lives.

Administration of the varicella zoster vaccine is safe in patients with rheumatoid arthritis or other rheumatic conditions who are taking biologic disease-modifying anti-rheumatic drugs, according to study results presented at the 2014 American College of Rheumatology annual meeting.

Adjusting treatment to maintain tight control of disease-related disability reduces mortality in rheumatoid arthritis, according to new research presented at the 2014 American College of Rheumatology annual meeting.

A Phase 3 trial of the monoclonal antibody secukinumab indicates it is an effective treatment for patients with ankylosing spondylitis (AS) incompletely treated by standard therapy, according to data presented at the 2014 American College of Rheumatology meeting.

The anti-arthritis drug hydroxychloroquine dramatically reduces the risk of cardiovascular morbidity and mortality in the disease, according to research presented here at the 2014 meeting of the American College of Rheumatology.

Study results show that antibiotic use in childhood more than doubles the risk of developing juvenile idiopathic arthritis.

Although change in knee joint space narrowing depicted on radiographs is considered the gold standard for monitoring osteoarthritis progression and knee cartilage volume loss, the method doesn't account for extrusion of the medial meniscus, which new research suggests can better predict radiographic osteoarthritis change over time.

During their "Great Debate" keynote session of the American College of Rheumatology (ACR) 2013 Annual Meeting in San Diego, CA, two leading rheumatologists took direct aim at each other's significant clinical trial data to provide rationale for choosing biologics over triple therapy - or vice versa - as the treatment of choice for rheumatoid arthritis (RA).

Though rheumatoid arthritis (RA) patients have a significantly higher risk of developing cardiovascular disease (CVD) compared to the general population, results from a pair of studies show that the biologic disease modifier Actemra (tocilizumab) may actually improve the cardiovascular (CV) profiles of RA patients.

Although rheumatologists have an array of disease measurement tools to choose from, they generally choose to ignore all of them when they're assessing rheumatoid arthritis (RA) patients.

As a follow-up to the initial establishment of Simponi (golimumab)'s safety and efficacy in rheumatoid arthritis (RA), researchers presented final 5-year data evaluating the tumor necrosis factor (TNF) blocker's effects in RA patients taking methotrexate and those naïve to the biologic agent.

Though previous reports have described a link between vitamin D deficiency and an increased risk of rheumatoid arthritis (RA) development, a trio of studies has now offered clinical support to the contrary belief.

Although methotrexate with or without glucocorticoids (GCs) is commonly used as a first-line treatment in rheumatoid arthritis (RA), study results show that combining the medication with two other traditional disease-modifying anti-rheumatic drugs (DMARDs) produces better outcomes in newly-diagnosed RA patients.

Noting that it takes an average of 5 years before a fibromyalgia patient receives a diagnosis, researchers conducted a retrospective data analysis to identify significant variables that may enable earlier detection and diagnosis of fibromyalgia.

Children born to mothers diagnosed with systemic lupus erythematosus (SLE) may be twice as likely to develop autism as those whose mothers don't have the chronic autoimmune disease.

There is a lot of work involved in producing a successful clinical trial. Even the planning stage alone can take a significant amount of time. But when data is incomplete-especially in longitudinal clinical trials-it can be a real struggle for organizers.

One of the more exciting parts of the conference has been the ability to sit in and listen to highlighted studies that are selected by the ACR. This press conference features Carol Wallace, MD, Seattle Children's Hospital and Research Institute, Seattle, WA, speaking about her study and answering questions from the audience.